AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9951899 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior mediastinal approach
Number of subjects: 38
Study 9951899 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior mediastinal approach
Number of subjects: 38
Study 9951899 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 38
Study 9951899 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (anterior and posterior)
Number of subjects: 38
Study 7806021 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady‐state focal electroretinogram at the macula
Number of subjects: 0
Study 2594898 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZ) 40 or 80 mg
Number of subjects: 8
Study 2594898 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (TZ) 1.0 or 2.0 mg
Number of subjects: 8
Study 2594898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 28474866 — intervention group
Group type: EXPERIMENTAL
Intervention: Gymnastics training (G)
Number of subjects: 12
Study 28474866 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 12
Study 27680484 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 30 μg/mL
Number of subjects: 47
Study 27680484 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 15 μg/mL
Number of subjects: 47
Study 25335375 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual bar design
Number of subjects: 15
Study 25335375 — intervention group
Group type: COMPARATOR
Intervention: Lingual plate design
Number of subjects: 15
Study 23523674 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate pegylated interferon alfa-2b treatment for 24 weeks
Number of subjects: 132
Study 23523674 — intervention group
Group type: COMPARATOR
Intervention: Delayed pegylated interferon alfa-2b plus ribavirin treatment starting 12 weeks after randomisation if HCV RNA remained positive
Number of subjects: 132
Study 23523674 — intervention group
Group type: COMPARATOR
Intervention: Delayed pegylated interferon alfa-2b plus ribavirin treatment
Number of subjects: 132
Study 23523674 — intervention group
Group type: COMPARATOR
Intervention: Immediate treatment (symptomatic or asymptomatic)
Number of subjects: 132
Study 23523674 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic patients receiving immediate treatment
Number of subjects: 132
Study 21355441 — intervention group
Group type: EXPERIMENTAL
Intervention: procaterol
Number of subjects: 14
Study 18296986 — intervention group
Group type: EXPERIMENTAL
Intervention: External nasal dilator (END)
Number of subjects: 23
Study 18296986 — intervention group
Group type: COMPARATOR
Intervention: Without external nasal dilator (without END)
Number of subjects: 23
Study 16571393 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation technique (FT) coupled with body weight‐supported treadmill training (BWSTT)
Number of subjects: 49
Study 16571393 — intervention group
Group type: COMPARATOR
Intervention: Mechanical assistance (control) during BWSTT
Number of subjects: 49
Study 16571393 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation technique (FT)
Number of subjects: 49
Study 16571393 — intervention group
Group type: COMPARATOR
Intervention: Mechanical assistance (control)
Number of subjects: 49
Study 14701891 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVIT study intervention (details not specified)
Number of subjects: 10
Study 12580236 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 12
Study 9538651 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase treatment (Group 2)
Number of subjects: 80
Study 9538651 — intervention group
Group type: EXPERIMENTAL
Intervention: No streptokinase treatment (Group 1)
Number of subjects: 80
Study 9538651 — intervention group
Group type: COMPARATOR
Intervention: Stable ischaemic heart disease (Control Group 3)
Number of subjects: 80
Study 9538651 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (Control Group 4)
Number of subjects: 80
Study 1493087 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (150 mg)
Number of subjects: 9
Study 1493087 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulphamethoxazole (160 and 800 mg)
Number of subjects: 9
Study 3895099 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cyclic therapy (using drugs like AMSA, 5-AZA, and HD-araC) during remission induction.
Number of subjects: 266
Study 3895099 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intensive remission induction.
Number of subjects: 266
Study 3895099 — intervention group
Group type: COMPARATOR
Intervention: Supportive care, 'wait and see' policy, and palliative cytoreduction with hydroxyurea and ara C when necessary.
Number of subjects: 266
Study 3895099 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance arm I (specific drugs not detailed).
Number of subjects: 266
Study 3895099 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance arm II (specific drugs not detailed).
Number of subjects: 266
Study 31012052 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell (RBC) transfusion at a hemoglobin level of ≤ 70 g·L–1 in the acute phase of care
Number of subjects: 218
Study 31012052 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell (RBC) transfusion at a hemoglobin level of ≤ 70 g·L–1 in the plateau phase of care
Number of subjects: 218
Study 29267940 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognition-Oriented Social Skills Training (MOSST)
Number of subjects: 69
Study 29267940 — intervention group
Group type: COMPARATOR
Intervention: Conventional Social Skills Training (SST)
Number of subjects: 69
Study 27629292 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-monthly paliperidone palmitate (PP)
Number of subjects: 444
Study 27629292 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral antipsychotics (COAs)
Number of subjects: 444
Study 27629292 — intervention group
Group type: COMPARATOR
Intervention: Atypical oral antipsychotics (AOAs)
Number of subjects: 444
Study 27629292 — intervention group
Group type: COMPARATOR
Intervention: Oral paliperidone/risperidone
Number of subjects: 444
Study 23782685 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training (box trainer or virtual reality simulator)
Number of subjects: 138
Study 23782685 — intervention group
Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 138
Study 22240495 — intervention group
Group type: EXPERIMENTAL
Intervention: MVD with CTO in a non-IRA
Number of subjects: 3283
Study 22240495 — intervention group
Group type: EXPERIMENTAL
Intervention: MVD without CTO
Number of subjects: 3283
Study 22240495 — intervention group
Group type: COMPARATOR
Intervention: SVD
Number of subjects: 3283
Study 20307730 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 31
Study 20307730 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 31
Study 18796619 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Care Protocol (task delegation to a practice nurse, computerized decision support, feedback every 3 months)
Number of subjects: 3391
Study 18796619 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 3391
Study 18796619 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Care Protocol
Number of subjects: 3391
Study 16552830 — intervention group
Group type: EXPERIMENTAL
Intervention: wen-jing-tang (unkei-to)
Number of subjects: 64
Study 16552830 — intervention group
Group type: COMPARATOR
Intervention: continuation of preceding Kampo prescription
Number of subjects: 64
Study 14700374 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (N = 20) heard the label of each verb 13 times while viewing the story
Number of subjects: 40
Study 14700374 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 20) did not hear the verbs' labels
Number of subjects: 40
Study 14700374 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental subgroup (N = 6) who correctly identified more than half of the target verbs
Number of subjects: 40
Study 14700374 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult group (N = 22) who did not view the story
Number of subjects: 40
Study 10821985 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cotinine
Number of subjects: 0
Study 10821985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9374603 — intervention group
Group type: EXPERIMENTAL
Intervention: Color photographs of the murder victim
Number of subjects: 120
Study 9374603 — intervention group
Group type: EXPERIMENTAL
Intervention: Black and white photographs of the murder victim
Number of subjects: 120
Study 9374603 — intervention group
Group type: COMPARATOR
Intervention: No photographs (control condition)
Number of subjects: 120
Study 9374603 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (color, black and white, no photographs)
Number of subjects: 120
Study 1311794 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 B‐estradiol (TTS 50; 50 mcg/day)
Number of subjects: 6
Study 1311794 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 B‐estradiol (TTS 50; 50 mcg/day) + Vaginal progesterone (P4; 100 mg twice daily)
Number of subjects: 6
Study 1311794 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 6
Study 4021803 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (1000 IU/day)
Number of subjects: 10
Study 4021803 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 10
Study 31818055 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Training (VT)
Number of subjects: 20
Study 31818055 — intervention group
Group type: COMPARATOR
Intervention: Standard Training (Control Group)
Number of subjects: 20
Study 31172667 — intervention group
Group type: EXPERIMENTAL
Intervention: FBCx + GINST15
Number of subjects: 400
Study 31172667 — intervention group
Group type: EXPERIMENTAL
Intervention: FBCx + placebo
Number of subjects: 400
Study 31172667 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo + GINST15
Number of subjects: 400
Study 31172667 — intervention group
Group type: COMPARATOR
Intervention: placebo + placebo
Number of subjects: 400
Study 28482621 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy and kinesitherapy
Number of subjects: 69
Study 28482621 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy
Number of subjects: 69
Study 28482621 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesitherapy
Number of subjects: 69
Study 28482621 — intervention group
Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 69
Study 25421475 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-451840 200 mg
Number of subjects: 0
Study 25421475 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-451840 500 mg
Number of subjects: 0
Study 25421475 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-451840 500 mg with food
Number of subjects: 0
Study 25421475 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-451840 200 mg and 500 mg
Number of subjects: 0
Study 25421475 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-451840
Number of subjects: 0
Study 22526973 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser dissection (L)
Number of subjects: 44
Study 22526973 — intervention group
Group type: COMPARATOR
Intervention: Standard stapler technique (S)
Number of subjects: 44
Study 21221004 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 429
Study 21221004 — intervention group
Group type: EXPERIMENTAL
Intervention: HUI mark III
Number of subjects: 429
Study 21221004 — intervention group
Group type: EXPERIMENTAL
Intervention: Both measures
Number of subjects: 429
Study 19500809 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance exercise (1-2 hours at 60% of peak oxygen consumption)
Number of subjects: 27
Study 19500809 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance exercise
Number of subjects: 27
Study 16837887 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (CEE) 0.625 mg daily and 2.5 mg of medroxyprogesterone acetate daily
Number of subjects: 92
Study 16837887 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol (TE2) 50 mcg twice weekly and 2.5 mg of medroxyprogesterone acetate daily
Number of subjects: 92
Study 16837887 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (CEE)
Number of subjects: 92
Study 14992985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (mean maximum dose=1.7 mg/day, SD=1.3)
Number of subjects: 22
Study 14992985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 14992985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 22
Study 11376503 — intervention group
Group type: EXPERIMENTAL
Intervention: Microstream capnometer (NBP‐75, Nellcor Puritan Bennett) with an aspiration flow rate of 30 ml.min‐1
Number of subjects: 30
Study 11376503 — intervention group
Group type: COMPARATOR
Intervention: Conventional sidestream capnometer with a 200 ml.min‐1 aspiration flow rate
Number of subjects: 30
Study 9262843 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux dialysis with ultrapure bicarbonate hemodialysis (HD)
Number of subjects: 23
Study 9262843 — intervention group
Group type: EXPERIMENTAL
Intervention: Predilution hemofiltration (HF)
Number of subjects: 23
Study 8111816 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day nifedipine
Number of subjects: 245
Study 8111816 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day nifedipine
Number of subjects: 245
Study 8111816 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg/day nifedipine
Number of subjects: 245
Study 8111816 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 245
Study 3713162 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee angle between 175-180°
Number of subjects: 16
Study 3713162 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee angle between 155-160°
Number of subjects: 16
Study 3713162 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee angle between 134-140°
Number of subjects: 16
Study 3713162 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 16
Study 30509244 — intervention group
Group type: EXPERIMENTAL
Intervention: Single row technique using two knotted 3.0 mm suture anchors
Number of subjects: 12
Study 30509244 — intervention group
Group type: EXPERIMENTAL
Intervention: Double row technique using an additional knotless 3.5 mm anchor
Number of subjects: 12
Study 30509244 — intervention group
Group type: COMPARATOR
Intervention: Single row technique
Number of subjects: 12
Study 27116931 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based eLearning training programme
Number of subjects: 130
Study 24475840 — intervention group
Group type: EXPERIMENTAL
Intervention: CE T1-weighted subtraction maps
Number of subjects: 160
Study 22488107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentosan Polysulfate Sodium (PPS), single oral dose
Number of subjects: 0
Study 22488107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentosan Polysulfate Sodium (PPS), daily oral doses for 8 weeks
Number of subjects: 0
Study 22488107 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin, lower doses than used for anticoagulation
Number of subjects: 0
Study 22488107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentosan Polysulfate Sodium (PPS)
Number of subjects: 0
Study 20829712 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEi (enalapril 20 mg/day) during high salt (200 mmol Na/day)
Number of subjects: 35
Study 20829712 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEi (enalapril 20 mg/day) during low salt (50 mmol Na/day)
Number of subjects: 35
Study 16988909 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g protein (14 g whey and casein protein, 6 g free amino acids)
Number of subjects: 19
Study 16988909 — intervention group
Group type: COMPARATOR
Intervention: 20 g dextrose placebo
Number of subjects: 19
Study 16195987 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (inspired O2 fraction = 16 %)
Number of subjects: 9
Study 16195987 — intervention group
Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 9
Study 11900103 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of 2 perceptually similar category members
Number of subjects: 0
Study 11900103 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing common labels for targets
Number of subjects: 0
Study 11900103 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing conflicting labels for targets
Number of subjects: 0
Study 10435264 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol self-administration study with naltrexone
Number of subjects: 21
Study 10435264 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 21
Study 7477988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB) 50 micrograms
Number of subjects: 3
Study 7477988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 2115348 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary instruction
Number of subjects: 0
Study 2115348 — intervention group
Group type: COMPARATOR
Intervention: Simple follow up without instruction (Control)
Number of subjects: 0
Study 7381649 — intervention group
Group type: EXPERIMENTAL
Intervention: 43 microgram HA vaccine
Number of subjects: 31
Study 7381649 — intervention group
Group type: COMPARATOR
Intervention: 10 microgram HA vaccine
Number of subjects: 31
Study 7381649 — intervention group
Group type: COMPARATOR
Intervention: 4 microgram HA vaccine
Number of subjects: 31
Study 31699651 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia
Number of subjects: 93
Study 31699651 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol
Number of subjects: 93
Study 31699651 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 93
Study 31699651 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall anesthesia types
Number of subjects: 93
Study 29508470 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline
Number of subjects: 8120
Study 29508470 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion
Number of subjects: 8120
Study 29508470 — intervention group
Group type: EXPERIMENTAL
Intervention: nicotine replacement therapy (NRT)
Number of subjects: 8120
Study 29508470 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8120
Study 25724391 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 115
Study 25724391 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 115
Study 23778240 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive couples‐based PMTCT intervention
Number of subjects: 239
Study 23778240 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 239
Study 22027579 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (15 mg, increased to 30 or 60 mg if needed)
Number of subjects: 120
Study 22027579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 22027579 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 120
Study 18722585 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced education residents
Number of subjects: 324
Study 18722585 — intervention group
Group type: COMPARATOR
Intervention: Control residents
Number of subjects: 324
Study 17944013 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of epinephrine (5 mg each)
Number of subjects: 2910
Study 17944013 — intervention group
Group type: COMPARATOR
Intervention: Standard doses of epinephrine (1 mg each)
Number of subjects: 2910
Study 17944013 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma patients discharged
Number of subjects: 2910
Study 17944013 — intervention group
Group type: COMPARATOR
Intervention: Medical patients discharged
Number of subjects: 2910
Study 15172463 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 22
Study 15172463 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary beta-radiation therapy (ICR)
Number of subjects: 22
Study 12134110 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-containing formula plus living Lactobacillus plantarum 299
Number of subjects: 95
Study 12134110 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-containing formula plus heat-killed Lactobacillus plantarum 299
Number of subjects: 95
Study 12134110 — intervention group
Group type: COMPARATOR
Intervention: Standard formula plus selective bowel decontamination (SBD)
Number of subjects: 95
Study 10488555 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition hypermnesia with alternative retrieval pathways
Number of subjects: 0
Study 10488555 — intervention group
Group type: EXPERIMENTAL
Intervention: Different recognition procedure with three test trials
Number of subjects: 0
Study 7574814 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy combined with hyperthermia
Number of subjects: 26
Study 7574814 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial chemotherapy alone
Number of subjects: 26
Study 2185964 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial wall extract plus bacterial ribosomes (Immucytal)
Number of subjects: 60
Study 2185964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 387498 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trithiozine
Number of subjects: 1000
Study 30835640 — intervention group
Group type: EXPERIMENTAL
Intervention: Video communication
Number of subjects: 40
Study 30835640 — intervention group
Group type: COMPARATOR
Intervention: Telephone communication
Number of subjects: 40
Study 30192007 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 2 mg/day
Number of subjects: 80
Study 30192007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 26514065 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic group therapy (20 weekly sessions)
Number of subjects: 167
Study 26514065 — intervention group
Group type: COMPARATOR
Intervention: Long-term psychodynamic group therapy (80 weekly sessions)
Number of subjects: 167